论文部分内容阅读
卡托普利是目前治疗充血性心力衰竭(CHF)最有前途的药物之一.我院1991年1月至1992年12月对收治的96例CHF患者中的48例使用卡托普利治疗,取得了较好的疗效,现予报道.1 资料与方法1.1 病例选择CHF96例,均为住院病人,男60例,女36例;年龄25～86(平均55.5)岁;心功能(NYHA分级法)Ⅲ级66例,Ⅳ级30例;高血压心脏病20例,风心病25例,扩张型心肌病14例,冠心病29例,其它8例.按住院顺序随机分为卡托普利治疗组(A组),常规治疗组(B组),每组48例.两组临床资料包括年龄、病程、心功能级别及疾病分布等无显著性差异.
Captopril is currently one of the most promising drugs for the treatment of congestive heart failure (CHF) in our hospital from January 1991 to December 1992 in 96 cases of CHF patients treated with captopril 48 , And achieved good curative effect, are reported.1 Materials and Methods 1.1 Case Selection CHF96 cases, all inpatients, 60 males and 36 females; aged 25 to 86 (average 55.5) years of age; cardiac function (NYHA classification France) 66 cases of grade Ⅲ, 30 cases of grade Ⅳ, 20 cases of hypertensive heart disease, 25 cases of rheumatic heart disease, 14 cases of dilated cardiomyopathy, 29 cases of coronary heart disease, the other 8 cases were randomly divided into captopril The treatment group (group A) and the conventional treatment group (group B), 48 cases in each group.The clinical data of two groups showed no significant difference in age, course of disease, cardiac function level and disease distribution.